Goldman Sachs’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-155,008
| Closed | -$620K | – | 6494 |
|
|
2025
Q2 | $620K | Sell |
155,008
-78,553
| -34% | -$195K | ﹤0.01% | 5037 |
|
|
2025
Q1 | $213K | Sell |
233,561
-19,161
| -8% | -$26.6K | ﹤0.01% | 5616 |
|
|
2024
Q4 | $700K | Sell |
252,722
-194,595
| -44% | -$740K | ﹤0.01% | 5054 |
|
|
2024
Q3 | $2.34M | Buy |
447,317
+85,449
| +24% | +$444K | ﹤0.01% | 4014 |
|
|
2024
Q2 | $1.61M | Sell |
361,868
-48,055
| -12% | -$233K | ﹤0.01% | 4076 |
|
|
2024
Q1 | $3.14M | Buy |
409,923
+46,551
| +13% | +$255K | ﹤0.01% | 3511 |
|
|
2023
Q4 | $1.55M | Buy |
363,372
+309,484
| +574% | +$1.1M | ﹤0.01% | 4112 |
|
|
2023
Q3 | $226K | Buy |
53,888
+19,499
| +57% | +$99.2K | ﹤0.01% | 4998 |
|
|
2023
Q2 | $192K | Buy |
+34,389
| New | +$203K | ﹤0.01% | 5198 |
|
|
2023
Q1 | – | Sell |
-11,924
| Closed | -$12.5K | – | 6074 |
|
|
2022
Q4 | $12.5K | Buy |
+11,924
| New | +$20.8K | ﹤0.01% | 5734 |
|
|
2022
Q3 | – | Sell |
-12,505
| Closed | -$60K | – | 6401 |
|
|
2022
Q2 | $60K | Sell |
12,505
-750
| -6% | -$3.26K | ﹤0.01% | 5991 |
|
|
2022
Q1 | $54K | Buy |
13,255
+16
| +0.1% | +$94 | ﹤0.01% | 6254 |
|
|
2021
Q4 | $90K | Sell |
13,239
-3,326
| -20% | -$28.7K | ﹤0.01% | 6161 |
|
|
2021
Q3 | $192K | Sell |
16,565
-2,745
| -14% | -$42.8K | ﹤0.01% | 5735 |
|
|
2021
Q2 | $329K | Sell |
19,310
-4,480
| -19% | -$77.9K | ﹤0.01% | 5467 |
|
|
2021
Q1 | $471K | Buy |
23,790
+2,951
| +14% | +$65.1K | ﹤0.01% | 5168 |
|
|
2020
Q4 | $430K | Buy |
20,839
+7,159
| +52% | +$171K | ﹤0.01% | 4697 |
|
|
2020
Q3 | $360K | Buy |
+13,680
| New | +$340K | ﹤0.01% | 4641 |
|
Goldman Sachs's INZY Position: Q3 2025 in Review
Goldman Sachs sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 155,008 shares — an estimated $620K sold.
Goldman Sachs first reported a position in INZY in Q3 2020 and held it in 18 quarters. The position peaked at $3.14M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Goldman Sachs reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 155,008 Inozyme Pharma shares in Q3 2025, an estimated $620K.
- Goldman Sachs first reported a position in Inozyme Pharma in Q3 2020 and held it in 18 quarters.
- Goldman Sachs's Inozyme Pharma position peaked at $3.14M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.